Northwestern University Feinberg School of Medicine

Parkinson's Disease and Movement Disorders Center

STAIR STUDY: An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects with Huntington's Disease (HD)

Clinical Trial Investigator:Danny Bega, MD

Aim: To assess the tolerability of SRX246 in irritable Subjects with early symptomatic HD over a period of 12 weeks compared to placebo.

The study drug, SRX246, has potential as a novel therapeutic agent for major neuropsychiatric symptoms seen in HD patients. This research study is being conducted to test its tolerability in HD patients with irritability, further assess its safety, and explore measures that can be employed in future trials to assess changes in these symptoms.  The study intervention will be given orally, in varied doses, twice daily. Approximately 150 HD patients with irritability will be screened to enroll 108 Subjects at about 20 NeuroNEXT sites.

Eligibility: You may be eligible to join the trial that is currently underway, if you meet the following criteria:

Study Duration: 3 months (12 weeks)

Compensation: Parking voucher provided

ALL STUDY RELATED MEDICATION/PROCEDURES ARE FREE OF CHARGE.

For More Information: Call us at (312) 503-2778.

Disclaimer

Northwestern Medicine and Northwestern University Feinberg School of Medicine will not release any of your personal information to 3rd parties, participating organizations and/or other institutions. Your information will only be available to the researcher(s) after you indicate interest in being contacted about a particular study.

Newly Diagnosed

Newly diagnosed with Parkinson’s disease and not yet treated? Please complete the Northwestern Medicine Parkinson’s Disease and Movement Disorders Center online appointment form to discuss next steps.

Feinberg is not a site of care. PDMDC faculty see patients through our affiliated clinic.